Phase 2 N=20 A Study in Participants With Acute Leukemia
Leukemia
Primary: Number of Participants With 1 or More Study Drug-Related Adverse Events (AEs) or Any Serious AEs (SAEs) — 6; 5; 6; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=21 Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma
ALL · B Cell Lymphoma · Leukemia
Primary: Number of Participants Who Received Preparative Chemotherapy Followed by Cluster of Differentiation (CD)19-Chimeric Antigen Receptor (CAR): CD19 CAR T-cells With < Grade…
Phase 3 N=108 A Study for Leukemia Patients With Life-Threatening Infections
Leukemia
Primary: Number of Participants Alive at Day 30 — 31; 39 Participants
Phase 2 N=29 Alemtuzumab (Campath) to Treat T-Large Granular Lymphocyte Leukemia
T-LGL Lymphoproliferative Disorders
Primary: Number of Participants With Hematological Response After Three Months of Alemtuzumab — 15 Participants
Phase 2 N=15 Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation
Leukemia
Primary: Efficacy of GM-CSF and Pegylated Interferon-alpha 2b When Administered to Patients With AML, ALL, Blast Phase CML, and MDS Relapse After Allogeneic Transplantation…
Phase 2 N=35 Acute Myeloid Leukaemia (AML) Patients Undergoing Induction Chemotherapy
Acute Myeloid Leukemia
Primary: Peak Aerobic Capacity (VO2peak) — 6.9; 7.4 metabolic equivalent (METS)
Phase 2 N=120 Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma
Lymphoblastic Leukemia · Lymphoblastic Lymphoma
Primary: 3-Year Event-Free Survival (EFS) — 68 Participants
Phase 2 N=73 Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia
Adult Acute Myeloid Leukemia · Secondary Acute Myeloid Leukemia · Therapy-Related Acute Myeloid Leukemia
Primary: Rate of Complete Remission and Mortality in the Entire Cohort of Older Patients — 21.9; 52.0 percentage of subjects
Phase 2 N=29 Clofarabine Bone Marrow Cytoreduction
Leukemia
Primary: Cytoreductive Response — 52 percentage of participants
N/A N=89 Vaccine Immune Recovery After Leukemia
Acute Lymphoblastic Leukemia, Pediatric
Primary: Incident Infection Rate in Participants During the First Year Post-acute Lymphoblastic Leukemia Therapy — 3.60 Events per person-year
Phase 2 N=34 Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia
Leukemia · Myelodysplastic Syndromes · Childhood Acute Myeloid Leukemia in Remission
Primary: Incidence of Engraftment — 100; 93; 100 Percentage of participants
Phase 2 N=4 Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy
Myelodysplastic Syndrome · Acute Myeloid Leukemia (AML) · Chronic Myeloid Leukemia (CML)
Primary: Cellular Immune Response — 4 participants
Phase 2 N=300 Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
Acute Undifferentiated Leukemia · B-cell Adult Acute Lymphoblastic Leukemia · B-cell Childhood Acute Lymphoblastic Leukemia
Primary: Maximum Tolerated Dose (MTD) of Alemtuzumab (Phase I) — 30 mg
Phase 2 N=77 Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Acute Biphenotypic Leukemia · Acute Leukemia of Ambiguous Lineage
Primary: Chronic GVHD — 17; 20; 14; 17 Participants
Phase 2 N=31 Stem Cell Transplantation for Patients With Cancers of the Blood
CML (Chronic Myelogenous Leukemia) · CLL (Chronic Lymphocytic Leukemia) · AML (Acute Myelogenous Leukemia)
Primary: To Determine if Selective T Cell Depletion Using the Photodepletion Procedure Can Substantially Reduce the Rate of Severe Acute GVHD (Grade III/IV) After Matched Sibling…
Phase 1 N=18 Clofarabine and Low Dose Total Body Irradiation as a Preparative Regimen for Stem Cell Transplant in Leukemia.
Leukemia Lymphoblastic, Acute · Acute Myeloid Leukemia · Neoplasm Recurrent
Primary: Maximum Feasible Dose of Clofarabine — 52 mg/m^2
Phase 1 N=72 A Trial In Patients With Advanced Cancer And Leukemia
Neoplasms by Histologic Type
Primary: Number of Solid Tumor Participants With First-Cycle Dose-Limiting Toxicity (DLT) — 0; 0; 0; 1 participants
Phase 2 N=15 LMB-2 to Treat Hairy Cell Leukemia
Hairy Cell Leukemia
Primary: Number of Patients Who Obtain Partial Response/Complete Remission — 1; 5 Participants
Phase 3 N=443 A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
Acute Myeloid Leukemia (AML)
Primary: Overall Survival (OS) — 9.6; 14.7 months — p=<0.001
Phase 2 N=32 Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients
Leukemia
Primary: Number of Participants (With Increase) Immune Response to GM-CSF With a Pneumococcal Vaccine — 0; 0; 1; 1 participants
Phase 3 N=624 Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation
Acute Leukemias of Ambiguous Lineage · Bacterial Infection · Diarrhea
Primary: Comparison of the Percentage of Patients Having Bacteremia Incidence Between Levofloxacin vs. No Prophylaxis Arms — 21.9; 43.4; 11; 17.3 Percentage of patients
Phase 2 N=116 Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants
Chronic Myelogenous Leukemia · Acute Myelogenous Leukemia · Chronic Lymphocytic Leukemia
Primary: Survival and Non-relapse Mortality at Day +200 Using the Miltenyi Reagent System — 43; 4 participants
Phase 3 N=170 Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma
Leukemia · Lymphoma
Primary: Complete Remission (CR) — 50; 50; 14; 11 participants
Phase 2 N=73 Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma
B Cell Leukemia · B Cell Lymphoma
Primary: Number of Subjects With Study Related Adverse Events. — 59 Participants
N/A N=102 Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute Leukemia
Acute Undifferentiated Leukemia · Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities · Adult Acute Myeloid Leukemia With Del(5q)
Primary: Treatment Related Mortality Defined as the Percent of Patients no Longer Alive at 60 Days After Registration — 91; 10 Participants
Phase 2 N=57 Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Adult Acute Lymphoblastic Leukemia in Remission
Primary: Disease Free Survival — 1.7 years
Phase 2 N=56 Blood Stem Cell Transplantation for the Treatment of Older Patients With Acute Myelogenous Leukemia
Acute Myelogenous Leukemia
Primary: Percentage of Participants With Relapse Free Survival at 1 Year — 56 percentage of participants
Phase 2 N=10 Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood
Leukemia, Acute Myelogenous (AML) · Leukemia, Acute Lymphocytic (ALL) · Leukemia, Chronic Myelogenous (CML)
Primary: Toxicity — 5 participants
Phase 2 N=15 Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia
Leukemia · Lymphocytic · Chronic
Primary: Response Rate — 0; 1; 3; 11 Participants
Phase 2 N=76 Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation
Myelodysplastic Syndrome · Acute Lymphocytic Leukemia · Acute Myelogenous Leukemia
Primary: Percentage of B Cells at One Year Post-transplant in Participants Who Did/Did Not Receive Leuprolide Following Bone Marrow Transplant (BMT) — 22.1; 21.9; 14.3 percentage…